Wegovy Indications for MASH
Belkis Llerena, Pharm.D., R.Ph, Novo Nordisk
On August 15, Wegovy received a new treatment indication from the FDA for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults.
MetroCare will host Belkis Llerena, Pharm.D., R.Ph, of Novo Nordisk to discuss the new indications, screening for fibrosis, and specific steps required for authorization for coverage by commercial payers and Medicare beginning Jan 1 2026.
This webinar is recommended for providers who care for at risk patients and staff involved in the authorization process.
Date: NOVEMBER 12
Time: 12:15
Location: Online only. Link will be emailed to registrants with reminder one day prior to the event.
*****NO CODING CEUs for this event*******
